Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.47 |
| ▸ | IL1RN | P18510 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7541485 | 0.86 | LTA4H (0.50) | LTA4HIL1RNERAP2ERAP1REN | |
| SCHEMBL7338616 | 0.82 | IL1RN (0.56) | LTA4HIL1RNERAP2ERAP1REN | |
| SCHEMBL7544107 | 0.82 | L3MBTL1 (0.49) | LTA4HIL1RNERAP2ERAP1REN | |
| SCHEMBL7338772 | 0.82 | IL1RN (0.56) | LTA4HIL1RNERAP2ERAP1REN | |
| SCHEMBL7542714 | 0.82 | LTA4H (0.49) | LTA4HIL1RNERAP2ERAP1REN | |
| SCHEMBL7547062 | 0.81 | CACNA1B (0.57) | IL1RNERAP2ERAP1 | |
| SCHEMBL7345226 | 0.81 | IL1RN (0.55) | LTA4HIL1RNERAP2ERAP1REN | |
| SCHEMBL7338162 | 0.81 | MME (0.56) | LTA4HIL1RNERAP2ERAP1REN | |
| SCHEMBL7344077 | 0.81 | PPARG (0.60) | LTA4HIL1RNERAP2ERAP1MME | |
| SCHEMBL7339872 | 0.79 | IL1RN (0.55) | LTA4HIL1RNERAP2ERAP1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362174-B1 | ANALGESICS, ANTIISCHEMIC AGENTS, ANTIEOILEPTIC AGENTS | WARNER-LAMBERT COMPANY | 2002-03-26 | — | — | US | disclosed |
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | RAFFERTY MICHAEL FRANCIS (US) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028801-A1 | Reduced dipeptide analogues as calcium channel antagonitsts | CACNA1E, RYR1, CACNA1B | LTA4H 2416/4885IL1RN 415/4885ERAP2 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.